APCCC 2024 | Evaluating triplet therapy in metastatic hormone sensitive prostate cancer

Nick James, MBBS, PhD, FRCP, FRCR, Institute of Cancer Research, London, UK, discusses the role of triplet systemic therapy in patients with metastatic hormone sensitive prostate cancer (mHSPC). Whilst there is existing literature on the addition of docetaxel followed by androgen deprivation therapy (ADT), there have not been any trials conducted on the efficacy of ADT followed by docetaxel. Prof. James subsequently details the subtle differences between the two regimens, as well as detailed findings from the STAMPEDE trial (NCT00268476). Overall, patients with synchronous or metachronous high volume disease will likely benefit from triplet therapy the most. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.